Sugi Predict
/ Targets
/ MDC1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to MDC1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency |
PHASE2/PHASE3 | RECRUITING |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) |
PHASE1/PHASE2 | RECRUITING |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations |
PHASE2 | COMPLETED |
| A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers |
PHASE2 | UNKNOWN |
| Pembrolizumab (MK-3475) in MM Patients With Residual Disease |
PHASE2 | COMPLETED |
| Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| Effects of Vitamin B3 in Patients With Ataxia Telangiectasia |
PHASE2 | COMPLETED |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma |
PHASE2 | RECRUITING |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors |
PHASE1 | RECRUITING |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin |
nan | RECRUITING |
| Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients |
nan | ACTIVE_NOT_RECRUITING |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer |
nan | UNKNOWN |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma |
nan | COMPLETED |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| Genetics of Prostate Cancer in Young Patients |
nan | COMPLETED |
| HRR Prevalence in LatAm PROSPECT Study |
nan | COMPLETED |
| A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. |
nan | ACTIVE_NOT_RECRUITING |
| Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility |
nan | RECRUITING |
| A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a MDC1 binder may also engage these)